{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:12:22Z","timestamp":1789693942679,"version":"4.0.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.annonc.2022.07.002","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T22:22:25Z","timestamp":1657750945000},"page":"1061-1070","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Toripalimab (anti-PD-1) versus high-dose interferon-\u03b12b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial"],"prefix":"10.1016","volume":"33","author":[{"given":"B.","family":"Lian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.H.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.N.","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.L.","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.X.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.Q.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.W.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.W.","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.L.","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.annonc.2022.07.002_bib1","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/cncr.20866","article-title":"Incidence of noncutaneous melanomas in the","volume":"103","author":"McLaughlin","year":"2005","journal-title":"U.S. Cancer"},{"issue":"4","key":"10.1016\/j.annonc.2022.07.002_bib2","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/annonc\/mdw694","article-title":"The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients","volume":"28","author":"Lian","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2022.07.002_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1471-2407-11-85","article-title":"Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases","volume":"11","author":"Chi","year":"2011","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.annonc.2022.07.002_bib4","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1245\/s10434-018-6503-9","article-title":"Multifactorial analysis of prognostic factors and survival rates among 706 mucosal melanoma patients","volume":"25","author":"Cui","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"16","key":"10.1016\/j.annonc.2022.07.002_bib5","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.1158\/1078-0432.CCR-13-0739","article-title":"Phase II randomized trial comparing high-dose IFN-alpha2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma","volume":"19","author":"Lian","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.annonc.2022.07.002_bib6","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/14712598.2020.1762561","article-title":"Toripalimab for the treatment of melanoma","volume":"20","author":"Tang","year":"2020","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"10.1016\/j.annonc.2022.07.002_bib7","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","article-title":"Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial","volume":"27","author":"Mai","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2022.07.002_bib8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1158\/1078-0432.CCR-21-2210","article-title":"Safety, efficacy, and biomarker analysis of toripalimab in patients with previously treated advanced urothelial carcinoma: results from a multicenter phase II trial POLARIS-03","volume":"28","author":"Sheng","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"32","key":"10.1016\/j.annonc.2022.07.002_bib9","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1200\/JCO.19.00210","article-title":"Axitinib in combination with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase IB trial","volume":"37","author":"Sheng","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2022.07.002_bib10","first-page":"139","article-title":"Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma","volume":"6","author":"Jonasch","year":"2000","journal-title":"Cancer J"},{"issue":"9","key":"10.1016\/j.annonc.2022.07.002_bib11","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1200\/JCO.2001.19.9.2370","article-title":"High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH\/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694\/S9512\/C509801","volume":"19","author":"Kirkwood","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.annonc.2022.07.002_bib12","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.annonc.2022.07.002_bib13","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.annonc.2022.07.002_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.13770","article-title":"Safety, antitumor activity, and pharmacokinetics of toripalimab, a programmed cell death 1 Inhibitor, in patients with advanced non-small cell lung cancer: a phase 1 trial","volume":"3","author":"Wang","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.annonc.2022.07.002_bib15","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.anorl.2017.02.003","article-title":"Sinonasal mucosal melanoma: a 44-case study and literature analysis","volume":"134","author":"Dr\u00e9no","year":"2017","journal-title":"Eur Ann Otorhinolaryngol Head Neck Dis"},{"issue":"1","key":"10.1016\/j.annonc.2022.07.002_bib16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/00016489.2019.1635269","article-title":"Impact of adjuvant therapy on survival for sinonasal mucosal melanoma","volume":"140","author":"Lai","year":"2020","journal-title":"Acta Otolaryngol"},{"issue":"6","key":"10.1016\/j.annonc.2022.07.002_bib17","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/01.coc.0000170805.14058.d3","article-title":"Head and neck mucosal melanoma","volume":"28","author":"Mendenhall","year":"2005","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2022.07.002_bib18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/DAD.0b013e3181a0d37c","article-title":"Primary oral mucosal melanoma: a series of 35 new cases from South America","volume":"31","author":"Louren\u00e7o","year":"2009","journal-title":"Am J Dermatopathol"},{"issue":"4","key":"10.1016\/j.annonc.2022.07.002_bib19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0305-7372(03)00074-4","article-title":"Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials","volume":"29","author":"Wheatley","year":"2003","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"10.1016\/j.annonc.2022.07.002_bib20","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/jnci\/djq009","article-title":"Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis","volume":"102","author":"Mocellin","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.annonc.2022.07.002_bib21","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2022.07.002_bib22","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2022.07.002_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2019.07.001","article-title":"Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial","volume":"119","author":"Eggermont","year":"2019","journal-title":"Eur J Cancer"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2022.07.002_bib24","article-title":"Overall survival and biomarker analysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with\u00a0metastatic mucosal melanoma","volume":"38","author":"Sheng","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2022.07.002_bib25","article-title":"CheckMate 067: Long-term outcomes in patients with mucosal melanoma","volume":"38","author":"Shoushtari","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2022.07.002_bib26","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cps.2021.05.010","article-title":"Mucosal melanoma","volume":"48","author":"Olla","year":"2021","journal-title":"Clin Plast Surg"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342201849X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342201849X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:14:30Z","timestamp":1760336070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375342201849X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S092375342201849X"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2022.07.002","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toripalimab (anti-PD-1) versus high-dose interferon-\u03b12b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2022.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}